Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens

Journal of the National Cancer Institute

Volumn 88, Issue 22, 1996, Pages 1635-1644

  Rosenberg, Steven A ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN;

CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER REGRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNIZATION, PASSIVE; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASMS; VACCINATION;

EID: 0029807749     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.22.1635     Document Type: Review

References (61)

1. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987;138:989-95.
2. Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988;168:1419-41.
3. Belldegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA. Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 1989;142: 4520-6.
4. O'Neil BH, Kawakami Y, Restifo NP, Bennink JR, Yewdell JW, Rosenberg SA. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Immunol 1993;151:1410-18.
5. Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 1993;151:5481-91.
6. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS, Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991;51:4257-65.
7. Hom SS, Rosenberg SA, Topalian SL. Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol Immunother 1993;36:1-8.
8. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992;12:1-12.
9. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmuller G, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-20.
10. Yang JC. Renal cell cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: Lippincott, 1995:262-9.
11. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2 [see comment citations in Medline]. JAMA 1994;271:907-13.
12. Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethe B, van den Eynde B, et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-50.
13. Rosenberg SA. A new perspective: the development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J Sci Am 1995;1:89-100.
14. Rosenberg SA. Cell transfer therapy: clinical applications. In: DeVita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: Lippincott, 1995:487-506.
15. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comment citation in Medline]. N Engl J Med 1988;319:1676-80.
16. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2 [see comment citation in Medline]. J Natl Cancer Inst 1994;86:1159-66.
17. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E. et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994;91:6458-62.
18. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Revoltini L, Topalian SL. et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994;91:3515-9.
19. Robbins PF, El-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy [published erratum appears in Cancer Res 1994;54:3952]. Cancer Res 1994;54:3124-6.
20. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995;181:1261]. J Exp Med 1995;181:799-804.
21. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92.
22. Robbins PF, El-Gamil M, Li Y, Topalian SL, Rivoltini L, Sakaguchi K, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-50.
23. Coulie P, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1995;180:1-4.
24. Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-9.
25. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor-infiltrating lymphocytes. J Exp Med 1994;180:347-52.
26. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T-lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
27. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9.
28. Brichard V, Van Pel A, Wolfel T, Wolfel C, DePlaen E, Lethe B, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
29. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction [see comment citation in Medline]. N Engl J Med 1990;323:570-8.
30. Topalian SL, Rivoltini L, Mancini M, Marcus NR, Robbins PF, Kawakami Y, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A 1994;91:9461-5.
31. Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. Cancer Res 1995;155:1343-8.
32. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996;183:1131-40.
33. Mattes MJ, Thomson TM, Old LJ, Lloyd KO. A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer 1983;32:717-21.
34. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
35. Su L-K, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993;262:1734-7.
36. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Science USA 1995;92:7976-80.
37. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al. A p16INK4A-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
38. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
39. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-75.
40. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-98.
41. Rosenberg SA, White DE. Brief report: Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996;183:1131-40.
42. Aebersold P, Hyatt C, Johnson S, Hines K, Korsak L, Sanders M, et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 1991;83:932-7.
43. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12:1475-83.
44. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
45. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-9.
46. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A* 0210 binding residues. J Immunol 1995;157:2539-48.
47. Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, Charmley P, et al. T Cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor infiltrating lymphocyte lines. Proc Natl Acad Sci U S A 1994;91:2829-33.
48. Cole DJ, Weil DP, Shamamian P, Rivoltini L, Kawakami Y, Topalian S, et al. Identification of MART-1 specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope [published erratum appears in Cancer Res 1994;54:6014]. Cancer Res 1994;54:5265-8.
49. Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, Rosenberg SA, et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 1995;55:748-52.
50. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995; 154:4685-92.
51. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996;156:238-45.
52. Bronte V, Tsung K, Rao J, Chen PW, Wang M, Rosenberg SA, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282-92.
53. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 1996; 156:224-31.
54. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 1996;156:3357-65.
55. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, et al. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 1996;56:2832-6.
56. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother 1995;19:266-77.
57. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. J Immunother. In press.
58. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Research 1996;56: 4749-57.
59. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol 1996;156:700-10.
60. Dadmarz R, Sgagias MK, Rosenberg SA, Schwartzentruber DJ. CD4+ T lymphocytes infiltrating human breast cancer recognize autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol Immunother 1995;40:1-9.
61. Dadmarz RD, Ordoubadi A, Mixon A, et al. Tumor infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC-class II restricted fashion. Cancer J Sci Am 1996;2:263-72.